Management Team


Jordan Lancaster, Ph.D. – Co-founder and Chief Executive Officer

Dr. Lancaster is an inventor of Avery’s MyCardia technology, which he developed at the University of Arizona. His two issued patents and several pending patents have been exclusively licensed to Avery. Dr. Lancaster’s research over the past decade has focused on cell-based regenerative medicine technologies for treating cardiovascular disease. His interests include engineered tissues using biomaterials and induced pluripotent stem cell derived cells. He holds a doctorate in Physiology from the University of Arizona and a certificate of Entrepreneurship from the Eller College.



Jen Koevary, Ph.D. – Chief Operating and Financial Officer

Dr. Koevary has a background in business development and medical device R&D. She was previously responsible for commercialization of university technology at the University of Arizona, where she led educational programs, community engagement programs for small business funding (including the U of A I-Corps Site program), business development assistance and the university’s asset development program, with >70 projects under management. Dr. Koevary has previously held high responsibility roles in startup companies Yakaroni, LLC and Surgical Tools, LLC, and has prior research and consulting experience in design and analysis for medical devices/software.Dr. Koevary earned a Ph.D. in Biomedical Engineering from the University of Arizona.



Steven Goldman, M.D. – Co-founder and Chief Medical Officer

Dr. Goldman is a board certified cardiologist and an inventor of Avery’s MyCardia technology, which was developed in his laboratories at the University of Arizona and Southern Arizona VA. Dr. Goldman is also Professor of Medicine and holds the C. Leonard Pfeffer Endowed Chair in Cardiovascular Research at the University of Arizona, Sarver Heart Center. He served as the Chief of Cardiology at the Southern Arizona VA for 35 years. Over the past 40 years his research has focused on understanding the pathophysiology of heart failure, developing new therapeutics for heart failure and graft patency after coronary artery bypass grafting. He has led multiple multi-center clinical trials and advised for several companies taking products through the FDA. His research lab has also performed contract research for a number of pharmaceutical companies including Merck, BI, Amgen and Novartis. Dr. Goldman earned his medical degree from the University of Cincinnati and completed Internal Medicine training at the University of Illinois, University of Chicago and Stanford, and his Cardiology Fellowship at Presbyterian Pacific Medical Center in San Francisco. Dr. Goldman served in the US Navy and Marine Corps in Vietnam and Long Beach, CA.


Scientific & Medical Advisors


Jack G. Copeland, M.D.

Dr. Copeland is the previous head of the cardiothoracic surgery program at the University of Arizona Medical Center in Tucson (retired). Dr. Copeland performed Arizona’s first heart transplant (1979), first heart-lung transplant (1985) and first U.S. implant of a pediatric ventricular assist device designed for newborns and toddlers (2000). Dr. Copeland brings years of experience in surgical approaches, patient populations, and immunology.


Jeffery Frelinger, Ph.D.

He brings years of experience in the genetics and biology of major histocompatibility complex (MHC) and immune response to organ transplant to the Avery team.


Elizabeth Juneman, M.D

Dr. Juneman is board certified in internal medicine, cardiovascular disease, echocardiography, nuclear cardiology and advanced heart failure/transplantation. She currently serves as Director of Advanced Heart Failure & Transplantation at the University of Arizona. Dr. Juneman’s basic science research focuses on understanding the electrical and mechanical remodeling in heart failure. Dr. Juneman has served as a principal investigator in nationally funded, multi-center clinical trials, as well as her own investigator-initiated clinical trials. She has authored multiple original research publications, book chapters, and multiple clinical reviews. She attended medical school at the University of Texas - Houston Health Sciences Center and completed her internal medicine residency & chief residency and cardiology fellowship at the University of Arizona (UA) College of Medicine in Tucson.


Tim Mobley, M.B.A.

Mr. Mobley is currently the Director of Glass Core Technology at Samtec.  Mr. Mobley obtained his MBA from Wharton. He brings expertise in technology commercialization, business strategy and relationship development to the Avery team.


Thomas Novak, Ph.D.

Dr. Novak was previously the VP, Life Sciences Business Development at Cellular Dynamics International (now a FujiFilm company), the world’s leading supplier of stem cell-derived cells. He was the Principal Investigator on CDI’s $16MM grant from the California Institute for Regenerative Medicine (CIRM) to reprogram samples from 3000 patients with a variety of multigenic disorders. Prior to joining CDI, Dr. Novak was Senior VP of Research and Development at Fate Therapeutics, a biotech developing small molecules and biologics to induce proliferation and differentiation of adult stem cells. Previously, Dr. Novak held a number of positions at Roche with responsibility for compound screening, cell culture, molecular biology, protein production, and crystallography.


Mike Siani Rose 

Mr. Siani Rose has 20+ years of experience in regenerative medicine, biotechnology and bioinformatics. He is currently a global project management consultant to Big Pharma/Biotech, directing projects that reach broadly across manufacturing organizations. Clients include Genentech/Roche, Kiverdi, Polymedics Innovations, Collaborative Drug Discovery (CDD), CommonPharma, and Onconetics. He received his BS in Chemical Engineering from the University of Rochester, did graduate work in Computer Science at UCSD, and attended the BioExecutive Institute in the Haas School of Business at UC Berkeley.



Michael Zile, M.D.

Dr. Zile is a professor of medicine and cardiologist with appointments at the Ralph H. Johnson Department of Veterans Affairs Medical Center and the Medical University of South Carolina.  He has expertise in diastolic function and clinical trial design and management to the Avery team.



MyCardia™ is engineered using induced pluripotent stem cells (iPSCs), which were recognized with the Nobel Prize in Physiology or Medicine (2012).



MyCardia™ behaves like cardiac tissue and mimics key molecular attributes of the heart. MyCardia™ is comprised of multiple cell types. Each provides a unique therapeutic role that synergistically repairs the heart.

Biologically Active


MyCardia™ is the future of regenerative medicine for the heart. MyCardia™ stimulates the body's repair mechanisms to grow new blood vessels and results in development of new cardiac tissue in treated areas.